Nucleotide oligomerization domain-containing proteins instruct T cell helper type 2 immunity through stromal activation Edited by Ruslan Medzhitov, Yale University School of Medicine, New Haven, CT, and approved July 18, 2011 (received for review October 12, 2010) Although a number of studies have examined the development of T-helper cell type 2 (Th2) immunity in different settings, the mechanisms underlying the initiation of this arm of adaptive immunity are not well understood. We exploited the fact that immunization with antigen plus either nucleotide-binding oligomerization domain-containing proteins 1 (Nod1) or 2 (Nod2) agonists drives Th2 induction to understand how these patternrecognition receptors mediate the development of systemic Th2 immune responses. Here, we show in bone-marrow chimeric mice that Nod1 and Nod2 expression within the stromal compartment is necessary for priming of effector CD4 + Th2 responses and specific IgG1 antibodies. In contrast, sensing of these ligands by dendritic cells was not sufficient to induce Th2 immunity, although these cells contribute to the response. Moreover, we determined that CD11c + cells were the critical antigen-presenting cells, whereas basophils and B cells did not affect the capacity of Nod ligands to induce CD4 + Th2 effector function. Finally, we found that full Th2 induction upon Nod1 and Nod2 activation was dependent on both thymic stromal lymphopoietin production by the stromal cells and the up-regulation of the costimulatory molecule, OX40 ligand, on dendritic cells. This study provides in vivo evidence of how systemic Th2 immunity is induced in the context of Nod stimulation. Such understanding will influence the rational design of therapeutics that could reprogram the immune system during an active Th1-mediated disease, such as Crohn's disease. D endritic cells (DCs) are thought to be the hub of generating adaptive immunity through their ability to present antigen and integrate danger signals to polarize naïve T cells toward different T-helper lineages. In this way, DCs are able to shape the quality of the adaptive immune response, ensuring that the response is specific for the type of infection that challenges a particular host. The signals that activate DCs to drive T-cell fate are a subject of interest, especially in the context of vaccination, because defining the molecular mechanisms underlying DC activation may allow manipulation of DCs to generate a desired adaptive immune response. Of the signals that have been studied to date, microbial-associated molecular patterns (MAMPs) and danger-associated molecular patterns (DAMPs) appear to be key triggers of DC activation and, consequently, important regulators of adaptive immunity.
Th2 immunity is important for killing extracellular pathogens and is characterized by the activation of CD4 + T cells producing IL-4, IL-5, IL-9, and IL-13 cytokines and a humoral response characterized the production mainly of IgG1 antibodies by B cells (1) . Moreover, Th2-associated mucosal inflammation is a common signature of human disorders affecting barrier surfaces, including allergy, asthma, ulcerative colitis, and parasitic infection. In terms of MAMPs and DAMPs that activate Th2 immunity, low concentrations of LPS-stimulating Toll-like receptor 4 (TLR4) and activation of Toll-like receptor 2 by certain agonists have been shown to induce Th2 immune responses (2, 3) . Aluminum hydroxide (alum), which is a key DAMP adjuvant used in human vaccines, is one of the best-studied triggers of Th2 immunity (4) . Some studies have suggested that the adjuvant activity of alum is mediated by the cytosolic nucleotide-binding oligomerization domain-containing protein (Nod)-like receptor (NLR), NLRP3 (5-7). However, these findings are controversial (8) (9) (10) , and there is a lack of consensus regarding the mechanisms by which alum induces systemic Th2 immunity (11, 12) . Although many naturally occurring allergens and allergenic extracts are used to study Th2-driven responses, these preparations often are contaminated with multiple MAMPs (13, 14) , thereby confounding the interpretation of the specific roles of different MAMPs in the generation of Th2 immunity in these contexts. The agonists that activate Nod1 and Nod2 receptors are chemically defined and have been shown to induce Th2 immunity (15, 16) , although the mechanisms underlying this response remain ill-defined.
We exploited the fact that specific triggering of Nod1 and Nod2 by their cognate ligands generates a specific Th2 immunity to examine the molecular mechanisms underlying the systemic development of this arm of adaptive immunity. Our results demonstrate an indispensable role of stromal-derived mediators, such as thymic stromal lymphopoietin (TSLP), in Nod-mediated Th2 induction. Indeed, Nod triggering in this compartment led to the production of factors, including TSLP, which are important for the up-regulation of OX40 ligand (OX40L) expression on DCs and subsequent Th2 induction. Importantly, although DCs in the hematopoietic compartment were absolutely required for antigen presentation, their direct stimulation by Nod ligands was insufficient to initiate Th2 immunity. Instead, our findings clearly show that licensing of antigen-loaded DCs through signals derived from the stroma is critical for the induction of the systemic Th2 immune response. This work identifies the molecular mechanisms that account for trans-activation of DCs leading to Th2 effector function upon Nod1 or Nod2 activation and provides a basis for the development of immunomodulators that would target Th2 differentiation specifically in vaccine and antiinfectious therapies.
Results
Ligand Sensing In Hematopoietic Cells Is Insufficient for Nod1-and Nod2-Driven Th2 Immunity. We first aimed to define in vivo if Nod1 and Nod2 activation within the hematopoietic compartment was able to generate Th2 immunity. We challenged WT→Nod2 −/− , WT→Nod1
, and WT→WT chimeric mice with ovalbumin (OVA) in the presence or absence of either the Nod2 agonist muramyl-dipeptide (MDP) or the Nod1 agonist FK156. T-cell and B-cell responses were examined by assessing the number of splenic cells producing IL-4 and IL-5 and the level of OVA-specific IgG1 antibodies in the sera, respectively. We observed that T-cell-and B-cell-mediated Th2 immunity triggered by OVA+MDP in WT→Nod2 −/− mice was abolished completely ( Fig. 1 A and B) , Similarly, WT→Nod1
−/− mice immunized with OVA+FK156 were incapable of mounting either T-cell (15) or B-cell Th2 immune responses ( Fig. 1 C and D) . Together, these findings demonstrate that Nod1 and Nod2 sensing within hematopoietic cells is insufficient to initiate Th2 immunity and instead point to a critical role for stromal mediators in initiating this arm of adaptive immunity.
Ligand Sensing in the Stromal Compartment Is Necessary for
Induction of Nod-Driven Th2 Immunity. Because hematopoietic cells from WT animals were unable to rescue Th2 induction driven by either the Nod1 or Nod2 agonist, we sought to determine if Nod1 or Nod2 signaling through the radioresistant compartment was required to induce Th2 immunity. We performed a reverse chimera experiment in which Nod1-or Nod2-deficient bone marrow (BM) was used to replenish WT animals. Specifically, WT, Nod1 → CBA/J mice had increased OT-II cell proliferation in response to OVA + FK156 or OVA + MDP immunization compared with the OVA control. However, the OT-II cells proliferated less in these chimeras than in the WT→CBA/J animals ( Fig. S1 A and B). T cells from the different chimeras proliferated to similar extents when alum was used as a control, demonstrating that the Nod1
CBA/J and Nod2
−/− →CBA/J chimeras can induce normal OT-II cell proliferation when another adjuvant is used (Fig. S1C ). This profile translated into the capacity of these cells to produce Th2 cytokines, because the OT-II cells from the Nod1
→CBA/J and Nod2
−/− →CBA/J mice produced IL-4 upon immunization with OVA+FK156 or OVA+MDP, respectively (Fig. S1D) . As with T-cell proliferation, we also observed that the responses were decreased by 30-50%, supporting the idea that Nod sensing by hematopoietic cells is required for optimal induction of Th2 immunity. Again, as a control, Nod deficiency in the hematopoietic compartment did not affect the ability of alum to induce Th2 immunity (Fig. S1E) .
We also measured OVA-specific T-cell activation and antibody production in chimeric animals in the absence of transferred OT-II cells. In this setting, T cells from FK156/MDP and OVAprimed Nod1 initiate Th2 immunity, but sensing within the hematopoietic compartment is required for a full response.
CD11c
+ Cell Populations Act as APCs for Nod-Driven Th2 Immunity.
We next sought to assess which cell populations are critical for antigen presentation in our model. We first showed that basophils (17) (18) (19) (20) (21) (22) are not required for Nod-driven Th2 differentiation (Fig. S2) . Because most studies in this regard have pointed to the key role of DCs as the main antigen-presenting cells during immunization or infection, we depleted CD11c + cells using the well-defined CD11c-diphtheria toxin receptor (DTR) model in which DTR is expressed on CD11c + cells and upon treatment with diphtheria toxin (DT), this cell population is selectively deleted (23) . Fig. 3A shows the efficiency of CD11c depletion analyzed by FACS after DT treatment compared with PBS injection as control. After DT treatment, CFSE-labeled OT-II cells were adoptively transferred into these mice and then immunized with OVA with or without MDP or FK156. We observed that these cells failed to proliferate in all immunization conditions following depletion of CD11c + cells (Fig. 3B) . In parallel, we also found that these OT-II T cells failed to produce IL-4 and that B cells did not produce OVA-specific antibodies (IgG1 b ) in immunized DT-treated CD11cDTR→CBA/J mice ( Fig. 3 C and D) 
Using B-cell-deficient μMT mice as well as mixed-BM μMT mice with Nod1-or Nod2-deficient B cells in our immunization protocol, we demonstrated that B cells are dispensable for optimal Th2 cell polarization induced by Nod ligands (Fig. S3) . We also demonstrated that direct ligand sensing by T cells was dispensable for Th2 induction by Nod ligands using OT-II mice crossed with Nod1-or Nod2-deficient mice as well as in a competitive assay with WT and Nod1-or Nod2-deficient OT-II cells (Fig.  S4) . Together, these data indicate that Nod signaling in T or B cells is not necessary for the induction of adaptive immunity driven by Nod ligands. Moreover, these findings further demonstrate that Nod1-or Nod2-deficient lymphocytes display no intrinsic defects in mediating adaptive Th2 immune activation.
We then focused on APCs and the possibility that direct Nod ligand sensing by CD11c + cells may modulate Th2 immunity. To investigate this possibility, we created mixed BM chimeric mice in which the CD11c + cell population of WT mice was of WT, Nod1-, or Nod2-deficient origin (Table S1 ). These mice then were recipients of adoptively transferred OT-II cells, to examine the specific activation of these cells by antigen. Nod1-or Nod2-deficient CD11c + cells in WT mice retained their ability to prime both T and B cells responses in the chimeric mice immunized with OVA with or without Nod agonists ( Fig. 3 E and F) . However, a significant reduction in these responses was observed, indicating that direct Nod ligand sensing by CD11c + cells is required for an optimal Th2 response.
TSLP and OX40 Promote Th2 Immunity Driven by Nod Ligands. To understand the mechanisms of Th2 differentiation induced by Nod ligands, we first examined the activation state of the CD11c + cell population in WT mice following OVA immunization with or without Nod agonists. As previously observed (24, 25) , Nod1 and Nod2 activation in vivo led to enhanced expression of a number of costimulatory molecules on CD11c + cells. Indeed, we observed that stimulation of Nod1 or Nod2 led to an increased surface expression of CD86, OX40L, and TSLP receptor (TSLPR) molecules and also CD40 for Nod1 stimulation (Fig. S5A) . Both OX40L-OX40 interactions and TSLP play key roles in promoting Th2 immunity (26, 27) . Therefore, we asked whether these molecules could mediate Nod-dependent Th2 differentiation. In both cases, OX40-and TSLP-deficient mice immunized with OVA plus either FK156 or MDP exhibited reduced ability of T cells to produce IL-4 and IL-5 and had fewer OVA-specific IgG1 antibodies in the serum (Fig. S5 B-E) . These findings are consistent with a critical role of OX40-OX40L interactions and TSLP in Nod-driven Th2 immunity. However, because the response was not completely abrogated in these settings, other factors likely contribute to Th2 induction by Nod proteins.
TSLP Is Produced by the Stromal Compartment Following Nod
Stimulation and Directs Th2 Immunity. Because of the significant role of TSLP on Nod-driven Th2 immunity, we were interested in examining which compartment produced TSLP and which cells need to receive the TSLP signal for induction of Th2 immunity in our model. To examine these questions, we created TSLP be delivered to hematopoietic cells to promote normal Th2 immunity, because both B-cell and T-cell responses were diminished in the chimeric mice with TSLPR-deficient BM (Fig. S6 B and C) . TSLP has been shown to act directly on DCs to up-regulate Th2-polarizing costimulatory molecules such as OX40L and also on T cells (28) (29) (30) . To assess if TSLP induced upon Nod1/2 activation in vivo acted directly on DCs to induce OX40L up-regulation, we generated BM chimeric mice in which only DCs were TSLPR deficient (Table. S1 ). We examined the activation state of the CD11c + cell population in these TSLPR +/+ DC→CBA/J and TSLPR −/− DC→CBA/J mice following immunization with OVA with or without Nod agonists or with LPS as a control. We observed that OX40L up-regulation on DCs was caused by the direct triggering of these cells by TSLP, whereas MHC class II increases were partially dependent on TSLP but not on CD40 or CD86 expression (Fig. 4A) .
Because we observed that (i) chimeric mice with TSLPR-deficient BM displayed defects in developing Th2 immunity upon OVA immunization in the context of Nod ligands and (ii) OX40L is induced upon a direct signal of TSLP on DCs, we then tested if Nod-stimulated TSLP promoted Th2 induction by acting directly on DCs. CFSE-labeled OT-II cells (TSLPR sufficient) were adoptively transferred into TSLPR −/− DC→CBA/J or TSLPR +/+ DC→CBA/J chimeric mice and were immunized on the next day with OVA with or without Nod agonists. In all conditions, T-cell proliferation was induced to a similar extent, indicating that TSLP-deficient signaling on DCs does not impact T-cell proliferation and survival (Fig. S7 A and B) . Surprisingly, we observed that the ability of T cells from these OT-II+ TSLPR −/− DC→CBA/J mice to produce IL-4 and IL-5 following stimulation was roughly 50% of the response seen in control OT-II+TSLPR +/+ DC→CBA/J mice (Fig. 4B) . Moreover, we observed a similar reduction of the Th2 response when OT-II cells were adoptively transferred to TSLPR −/− →CBA/J mice in the same experimental conditions (Fig. S7 C and D) , further supporting the idea that TSLP acts primarily on DCs to mediate Th2 immunity following Nod1 and Nod2 stimulation.
Discussion
Although adjuvants like Nod agonists and alum promote the systemic development of the Th2 arm of the adaptive immune response, the mechanisms underlying Th2 polarization by these compounds are poorly defined (31) . Using specific Nod agonists in vivo, we show the absolute requirement of the stromal compartment for sensing Nod ligands to initiate Th2 immunity. DCs were defined as the APC in this model, and although direct stimulation of DCs by Nod agonists failed to initiate Th2 immunity, this stimulation optimized the response. Probing the mechanism of Th2 initiation by Nod stimulation, we uncovered a role for OX40L-OX40 signaling downstream of TSLP induction. Together, these results reveal the importance of the Nod-driven TSLP-OX40 axis in orchestrating the communication between stromal and hematopoietic cells for the induction of systemic Th2 immunity. The question of whether trans priming of DCs in vivo can lead to the development of effector adaptive immunity has been examined previously in the context of TLR stimulation. Previous work demonstrated that APCs activated in trans by inflammation emanating from the stroma are not competent for differentiating T cells along the Th1 axis at the systemic level (32) . Accordingly, only direct triggering of TLRs on APCs can generate Th1 adaptive immunity in this context. In support of these findings, APCs selectively deleted for the TLR adaptor, MyD88, are unable to support Th1 polarization of antigen-specific CD4 + T cells following stimulation of mice with a soluble TLR ligand. Direct DC licensing by TLR stimulation, therefore, appears to be a requirement for systemic Th1 induction (32) . In contrast, our work revealed that the Nod-driven development of the Th2 arm of adaptive immunity involved licensing of DCs in trans by signals emanating from the stromal compartment. This concept of trans activation is an emerging theme in the field of lung mucosal immunology where structural cells such as epithelial cells, fibroblasts, and other stromal cells are thought to produce activating cytokines that determine the quantity and quality of the lung immune response. For example, house dust mite allergen induces Th2-associated asthma dependent on the expression of TLR4 in the radioresistant lung structural cells (33) . This activation process therefore might be a general feature of Th2 immune induction and underscores the necessity of studying the mechanisms of Th2 differentiation in vivo.
The mechanism by which Nod activation leads to differentiation of Th2 immunity was found to depend, in part, on the TSLP-OX40 axis. TSLP-deficient mice had diminished capabilities in generating Th2 immunity to antigen in the context of Nod stimulation. Stromal sources of TSLP appeared to be important for Th2 induction, and although we were not able to pinpoint the cellular source of this cytokine, we found that epithelial cells in vitro were able to produce TSLP after Nod1 or Nod2 stimulation (Fig. S8) , suggesting that these cells might be one important component of this signaling network. At the mucosal level, TSLP is thought to promote Th2 immunity by up-regulating the expression of OX40L and other costimulatory molecules on DCs as well as inducing the production of soluble mediators critical for the recruitment and activation of Th2 cells (28, 34, 35) . In line with this effect, we found that Nod stimulation induced the up-regulation of OX40L expression on DCs, and mice deficient in OX40 had diminished capabilities in generating Nod-driving Th2 immunity. Because OX40 also appears to be important for regulating the induction regulatory T cells and modifying their function, it is of interest to examine how Nod stimulation might affect suppressive activities of these cells. Recent findings have shown that Nod2 stimulation in the context of airway inflammation blocks induction of CD4 + Foxp3 + adaptive T-regulatory cells while enhancing effector functions of CD4 + T cells (36) . We next examined the mechanism underlying the Th2-promoting activity of TSLP in vivo following Nod activation. Using TSLP-deficient mice and chimeric animals with TSLPR-deficient DCs, we found that TSLP acting on DCs is required for Nodstimulated Th2 immunity. Indeed, upon immunization with OVA plus Nod ligands, T cells capable of responding to TSLP from the stroma in mice that had TSLPR-deficient DCs were able to proliferate but lacked full effector cytokine expression. Only when DCs expressed TSLPR was T-cell effector function restored completely, thereby demonstrating that TSLP stimulation directly on DCs is required to mediate full systemic Th2 immune responses.
Polymorphisms in the genes encoding Nod1 and Nod2 have been associated with human diseases characterized by inflammation of barrier tissues. Indeed, both Nod1 and Nod2 have been linked to inflammatory bowel disease (37, 38) and asthma (39) (40) (41) (42) . Dysregulated Th2 induction probably underlies the pathogenesis of both of these disorders. Indeed, the implication of Nod1 in asthma might stem from overactivation of the molecule because of an inability to up-regulate spliced isoforms that lack ligand-sensing capabilities (43) , leading to the aberrant Th2 inflammation that characterizes asthma. Additionally, in recent work, Nod2 was shown to break tolerance to an inhaled antigen, uncovering the potential of Nod2 in driving Th2 lung inflammation (36) . On the other hand, lack of MDP sensing by the Crohn's disease-associated mutation in Nod2 (44) could result in the inability to drive Th2 regulatory signals that control intestinal mucosal homeostasis. Our work underscores the importance of identifying the mediators of Th2 immunity driven by Nod1 and Nod2 to provide a framework toward the development of therapeutic strategies targeting these diseases.
Materials and Methods
Mice. All animal experiments were approved by the Animal Ethics Review Committee of the University of Toronto and performed according to local guidelines. C57BL/6(H-2 b , CD45.2) mice were purchased from Charles River Laboratories. CBA/J(H-2 k ), CD11c-DTR(H-2 b ), C57BL/6(H-2 b , CD45.1), and μMT mice were purchased from The Jackson Laboratory. −/− mice were described previously (46) . OT-II Thy1.2 and OT-II Thy1.1 transgenic mice were gifts from Tania Watts and Jennifer L. Gommerman (Department of Immunology, University of Toronto, Toronto, ON, Canada), respectively. All mice were bred and maintained under specific pathogen-free conditions at the University of Toronto animal 
